BRCA1 and ovarian carcinoma: In the present study, we have assessed the aberrant promoter hypermethylation status of RASSF1a and BRCA1 in the cell-free circulating DNA (cfc DNA) of ovarian carcinoma patients using methylation-specific PCR.